PDF herunterladen
Semin Thromb Hemost 2016; 42(01): 042-054
DOI: 10.1055/s-0035-1568875
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis

Nicoletta Riva
1   Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
,
Francesco Dentali
1   Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
,
Eleonora Tamborini Permunian
1   Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
,
Walter Ageno
1   Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
11. Januar 2016 (online)

    Lizenzen und Reprints

Abstract

The novel direct oral anticoagulants (DOACs) have been proposed as alternatives to low-molecular-weight heparins (LMWHs) for the prevention of venous thromboembolism in orthopedic surgery. However, the clinical impact of postsurgical bleeding with the DOACs has not been extensively evaluated. MEDLINE and EMBASE databases, supplemented with conference abstract books and www.clinicaltrial.gov, were searched up to the first week of March 2015. We included phase II and phase III randomized controlled trials comparing the DOACs with LMWHs in patients undergoing major orthopedic surgery. Data regarding major, fatal, and intracranial bleeding were collected, to calculate the pooled relative risk (RR) and the case-fatality rate (CFR), with 95% confidence interval (CI). We retrieved 25 studies (5 evaluating dabigatran, 4 apixaban, 6 edoxaban, and 10 rivaroxaban), enrolling 42,170 patients. There was no significant difference between the DOACs and LMWHs in the risk of major (1.23 vs. 1.16%; RR: 1.07, 95% CI: 0.89–1.29), fatal (0.02 vs. 0.01%; RR: 1.63, 95% CI: 0.39–6.77), and intracranial bleeding (0 vs. 0.01%; RR: 0.33, 95% CI: 0.03–3.18). The weighted mean CFR of major bleeding was 3.3% (95% CI, 1.5–5.7) and 2.3% (95% CI, 0.7–4.6), respectively. Bleeding complications and the associated CFR during prophylactic anticoagulation in orthopedic surgery were very low and not significantly different between the DOACs and LMWHs.

Keywords

direct oral anticoagulant - low-molecular-weight heparin - major bleeding - meta-analysis - orthopedic surgery

Supplementary Material

 

  • References

  • 1 Falck-Ytter Y, Francis CW, Johanson NA , et al; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl): e278S-e325S
    CrossrefPubMedGoogle Scholar
  • 2 Geerts WH, Bergqvist D, Pineo GF , et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl): 381S-453S
    CrossrefPubMedGoogle Scholar
  • 3 Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real-world issues. Semin Thromb Hemost 2011; 37 (6) 653-663
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Barnes GD, Ageno W, Ansell J, Kaatz S ; Subcommittee on the Control of Anticoagulation. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (6) 1154-1156
    CrossrefPubMedGoogle Scholar
  • 5 Quinlan DJ, Eriksson BI. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. Best Pract Res Clin Haematol 2013; 26 (2) 171-182
    CrossrefPubMedGoogle Scholar
  • 6 Neumann I, Rada G, Claro JC , et al. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 2012; 156 (10) 710-719
    CrossrefPubMedGoogle Scholar
  • 7 Salazar CA, Malaga G, Malasquez G. Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. Cochrane Database Syst Rev 2010; (4) CD005981
    PubMedGoogle Scholar
  • 8 Nieto JA, Espada NG, Merino RG, González TC. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thromb Res 2012; 130 (2) 183-191
    CrossrefPubMedGoogle Scholar
  • 9 Moher D, Liberati A, Tetzlaff J, Altman DG ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151 (4) 264-269 , W64
    CrossrefPubMedGoogle Scholar
  • 10 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33 (1) 159-174
    CrossrefPubMedGoogle Scholar
  • 11 Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost 2010; 8 (9) 1966-1975
    CrossrefPubMedGoogle Scholar
  • 12 Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8 (1) 202-204
    CrossrefPubMedGoogle Scholar
  • 13 Center for Drug Evaluation and Research. Medical review. Application number: 022406. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000MedR.pdf . Accessed March 15, 2015
    PubMedGoogle Scholar
  • 14 Higgins JP, Altman DG, Gøtzsche PC , et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
    CrossrefPubMedGoogle Scholar
  • 15 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22 (4) 719-748
    PubMedGoogle Scholar
  • 16 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (3) 177-188
    CrossrefPubMedGoogle Scholar
  • 17 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004; 23 (9) 1351-1375
    CrossrefPubMedGoogle Scholar
  • 18 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414) 557-560
    CrossrefPubMedGoogle Scholar
  • 19 Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323 (7304) 101-105
    CrossrefPubMedGoogle Scholar
  • 20 Fuji T, Fujita S, Tachibana S , et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 3320
    CrossrefPubMedGoogle Scholar
  • 21 Dose-confirmatory bridging study in total hip replacement . Available at: http://www.clinicaltrial.gov/ct2/show/NCT01205932 . Accessed March 15, 2015
    PubMed
  • 22 Dose-confirmatory bridging study in total knee replacement . Available at: http://www.clinicaltrial.gov/ct2/show/NCT01206972 . Accessed March 15, 2015
    PubMed
  • 23 Eriksson BI, Dahl OE, Rosencher N , et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370 (9591) 949-956
    CrossrefPubMedGoogle Scholar
  • 24 Eriksson BI, Dahl OE, Rosencher N , et al; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5 (11) 2178-2185
    CrossrefPubMedGoogle Scholar
  • 25 Ginsberg JS, Davidson BL, Comp PC , et al; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 26 Eriksson BI, Dahl OE, Huo MH , et al; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105 (4) 721-729
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 27 Mirdamadi A, Dashtkar S, Kaji M, Pazhang F, Haghpanah B, Gharipour M. Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. ARYA Atheroscler 2014; 10 (6) 292-297
    PubMedGoogle Scholar
  • 28 Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5 (12) 2368-2375
    CrossrefPubMedGoogle Scholar
  • 29 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361 (6) 594-604
    CrossrefPubMedGoogle Scholar
  • 30 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P ; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375 (9717) 807-815
    CrossrefPubMedGoogle Scholar
  • 31 Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM ; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363 (26) 2487-2498
    CrossrefPubMedGoogle Scholar
  • 32 Raskob G, Cohen AT, Eriksson BI , et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010; 104 (3) 642-649
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 33 Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 2014; 29 (12) 2439-2446
    CrossrefPubMedGoogle Scholar
  • 34 Fuji T, Wang CJ, Fujita S , et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res 2014; 134 (6) 1198-1204
    CrossrefPubMedGoogle Scholar
  • 35 Fuji T, Fujita S, Kawai Y , et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res 2014; 133 (6) 1016-1022
    CrossrefPubMedGoogle Scholar
  • 36 Fuji T, Fujita S, Kawai Y , et al. A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. Thromb J 2015; 13 (1) 6
    CrossrefPubMedGoogle Scholar
  • 37 Turpie AG, Fisher WD, Bauer KA , et al; OdiXa-Knee Study Group. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3 (11) 2479-2486
    CrossrefPubMedGoogle Scholar
  • 38 Eriksson BI, Borris LC, Dahl OE , et al; ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114 (22) 2374-2381
    CrossrefPubMedGoogle Scholar
  • 39 Eriksson BI, Borris L, Dahl OE , et al; ODIXa-HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4 (1) 121-128
    PubMedGoogle Scholar
  • 40 Eriksson BI, Borris LC, Dahl OE , et al. Dose-escalation study of rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120 (5) 685-693
    CrossrefPubMedGoogle Scholar
  • 41 Eriksson BI, Borris LC, Friedman RJ , et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358 (26) 2765-2775
    CrossrefPubMedGoogle Scholar
  • 42 Kakkar AK, Brenner B, Dahl OE , et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372 (9632) 31-39
    CrossrefPubMedGoogle Scholar
  • 43 Lassen MR, Ageno W, Borris LC , et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26) 2776-2786
    CrossrefPubMedGoogle Scholar
  • 44 Turpie AG, Lassen MR, Davidson BL , et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373 (9676) 1673-1680
    CrossrefPubMedGoogle Scholar
  • 45 Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010; 3 (6) 652-660
    CrossrefPubMedGoogle Scholar
  • 46 Cao YB, Zhang JD, Shen H, Jiang YY. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010; 66 (11) 1099-1108
    CrossrefPubMedGoogle Scholar
  • 47 Turun S, Banghua L, Yuan Y, Zhenhui L, Ying N, Jin C. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb Res 2011; 127 (6) 525-534
    CrossrefPubMedGoogle Scholar
  • 48 Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 2011; 105 (2) 245-253
    PubMedGoogle Scholar
  • 49 Friedman RJ, Dahl OE, Rosencher N , et al; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010; 126 (3) 175-182
    CrossrefPubMedGoogle Scholar
  • 50 Beyer-Westendorf J, Lützner J, Donath L , et al. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. Thromb Haemost 2013; 109 (1) 154-163
    PubMedGoogle Scholar
  • 51 van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (3) 320-328
    CrossrefPubMedGoogle Scholar
  • 52 Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126 (20) 2381-2391
    CrossrefPubMedGoogle Scholar
  • 53 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139 (11) 893-900
    CrossrefPubMedGoogle Scholar
  • 54 Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol 2013; 70 (12) 1486-1490
    PubMedGoogle Scholar